Pancreatic Cancer Research

ResearcherThird Affiliated Hospital of Southern Medical UniversityActive in the last 2 years

Yingfang Fan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2550-7954; OpenAlex author ID A5085538327. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
18
Papers, trials and grants by year

2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers

Papers 11

  1. The role of histone H1.2 in pancreatic cancer metastasis and chemoresistance. Co-author DOI 10.1016/j.drup.2023.101027↗
  2. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC. Last author DOI 10.1016/j.drup.2024.101079↗
  3. GAP-43 targeted indocyanine green-loaded near-infrared fluorescent probe for real-time mapping of perineural invasion lesions in pancreatic cancer in vivo. Last author DOI 10.1016/j.nano.2023.102671↗
  4. Development and Validation of a Nomogram for Preoperative Prediction of Early Recurrence after Upfront Surgery in Pancreatic Ductal Adenocarcinoma by Integrati… Co-author DOI 10.3390/cancers15143543↗
  5. A nanomedicine enables synergistic chemo/photodynamic therapy for pancreatic cancer treatment. Co-author DOI 10.1039/d2bm00437b↗
  6. Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer. Last author DOI 10.1186/s12943-022-01587-9↗
  7. TMPRSS4 Promotes Cell Proliferation and Inhibits Apoptosis in Pancreatic Ductal Adenocarcinoma by Activating ERK1/2 Signaling Pathway. Last author DOI 10.3389/fonc.2021.628353↗
  8. Establishing and validating a pathway prognostic signature in pancreatic cancer based on miRNA and mRNA sets using GSVA. Co-author DOI 10.18632/aging.103965↗
  9. Activating miRNA-mRNA network in gemcitabine-resistant pancreatic cancer cell associates with alteration of memory CD4+ T cells. Co-author DOI 10.21037/atm.2020.03.53↗
  10. MiR-24-3p Inhibits the Progression of Pancreatic Ductal Adenocarcinoma Through LAMB3 Downregulation. Last author DOI 10.3389/fonc.2019.01499↗
  11. miR-23a-5p inhibits cell proliferation and invasion in pancreatic ductal adenocarcinoma by suppressing ECM1 expression. Co-author PMID 31217868↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jianyou Gu · 7 shared papers, 2019–2024 · strength 0.98
  2. Huaizhi Wang · 7 shared papers, 2019–2024 · strength 0.88
  3. Wenjie Huang · 4 shared papers, 2019–2024 · strength 0.53
  4. Tian Tao · 4 shared papers, 2019–2022 · strength 0.48
  5. Junfeng Zhang · 2 shared papers, 2020–2024 · strength 0.29
  6. Shixiang Guo · 2 shared papers, 2020–2024 · strength 0.29
  7. Liwei Zhu · 2 shared papers, 2021–2022 · strength 0.27
  8. Xianxing Wang · 2 shared papers, 2020–2021 · strength 0.23
  9. Wen Liang Lu · 1 shared paper, 2023 · strength 0.22
  10. Sheng Yan · 1 shared paper, 2023 · strength 0.20
  11. Fei Xiang · 1 shared paper, 2023 · strength 0.20
  12. Fuming Xie · 1 shared paper, 2024 · strength 0.19
  13. Qing Chen · 1 shared paper, 2024 · strength 0.19
  14. Jin Geng · 1 shared paper, 2022 · strength 0.15
  15. Junfeng Zhang · 1 shared paper, 2021 · strength 0.12
  16. Jianyou Gu · 1 shared paper, 2021 · strength 0.12
  17. Bing Ni · 1 shared paper, 2020 · strength 0.11
  18. Songsong Liu · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.